feedback

Provided By

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: August 8, 2017
Expires: August 8, 2018
1 hour to complete

Target Audience

Community medical oncologists, radiation oncologists, hematologists, hematologist/oncologists, internists, oncology nurse practitioners (NPs), physician assistants (PAs), nurses, and other clinicians involved in the management of patients with MM.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss new treatment options stemming from recent FDA approvals in the relapsed/refractory setting.
  2. Review recently published clinical trial data on the efficacy and safety of emerging treatments for relapsed/refractory patients.
  3. Describe recent changes to clinical practice guidelines affecting care for patients with relapsed/refractory disease.
  4. Summarize best practices with respect to communication and coordination among members of the multidisciplinary myeloma care team.

Activity Description

This activity will examine tailored treatment approaches for patients with relapsed/refractory multiple myeloma.

Statement of Educational Need

The treatment landscape for multiple myeloma (MM) is rapidly evolving. FDA approval of 10 new agents in the past 12 years has changed the natural history of this plasma cell malignancy. Survival among relapsed/refractory patients has doubled, while survival among newly diagnosed patients has improved by 50%. Some authorities now claim that young, fit patients with favorable risk factors can be cured with aggressive treatment; however, the management of patients who relapse remains a challenge.

Agenda

  • Introduction
  • Case study 1
  • Recent FDA approvals and new options in relapsed/refractory setting
  • Updates to clinical practice guidelines
    • US guidelines
    • International guidelines
    • Teaching point: Most important updates related to treating relapsed/refractory patients
  • Clinical trials in MM
    • Novel targets and pathways
    • Novel agents
    • Novel combinations and treatment strategies
    • Teaching point: Clinical trials most relevant to treating relapsed/refractory patients
  • Case study 2
  • Team-based approaches to care
    • Importance of team-based care in improving patient outcomes
    • Supportive roles of various multidisciplinary team members
    • Best practices in communication and care coordination
    • Nursing and pharmacy implications of treating with monoclonal antibodies
    • Toxicity management
    • Insurance approval
  • Conclusion

Presenter

Joseph R. Mikhael MD, MEd, FRCPC, FACP
Professor of Medicine
Mayo College of Medicine
Associate Dean
Mayo School of Graduate Medical Education
Deputy Director – Education Mayo Clinic Cancer Center
Phoenix, AZ


Additional Content Development Faculty

Saad Z. Usmani, MD, FACP
Chief, Plasma Cell Disorders
Director, Clinical Research in Hematologic Malignancies
Clinical Professor of Medicine, UNC-Chapel Hill School of Medicine
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute/Carolinas HealthCare System
Charlotte, NC

Ajai Chari, MD, PhD
Associate Professor of Medicine
Division of Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosure of Conflict of Interest

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.

Dr. Mikhael has disclosed the following:
Research Grant: AbbVie, Celgene, Sanofi

Dr. Usmani has disclosed the following:
Speakers Bureau: Amgen, Celgene, Takeda
Consultant/Advisor: Amgen, Celgene, Janssen, SkylineDX
Research Grant: Amgen, Celgene, Janssen, Takeda, Sanofi, Array BioPharma

Dr. Chari has disclosed the following:
Consultant/Advisor: Array BioPharma, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Millennium, Amgen
Research Grant: Array BioPharma, Celgene, Janssen, Novartis, Millennium, Onyx, Pharmacyclics

Penn State staff involved in the development and review of this activity have nothing to disclose.

MCM Education staff involved in the development and review of this activity have nothing to disclose.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Penn State College of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating in or receiving credit for this educational activity. Credit is awarded to participants who score 80% or better on the post-test.

Statement of Commercial Support

Supported by independent educational grants from Amgen; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Oncology.

Disclaimer Statement / Disclosure of Unlabeled Use

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; Amgen; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; or Takeda Oncology. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Contact Information for Questions about the Activity

For questions regarding CME credit, contact Penn State Continuing Education at 717-531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6194-18-T.

Hardware / Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.